Registry-only phase 2 and 3 trials that name lung, non-small-cell lung or small-cell lung cancer in their title or conditions, recorded from ClinicalTrials.gov during the lung cancer deep dive of September 2026; registry facts only, no outcomes. 323 records carry it: 323 trials.
A phase 3 trial of IN10018, tislelizumab, carboplatin and pemetrexed in lung cancer, run by Shanghai Jeyou Pharmaceutical Co., Ltd., not yet recruiting.
A phase 2 trial of adebrelimab, carboplatin, cisplatin and etoposide in lung cancer, run by Nanfang Hospital, Southern Medical University, now recruiting.
A phase 2/3 trial of adebrelimab, SHR-8068, pemetrexed, carboplatin and other drugs in lung cancer, run by Shanghai Shengdi Pharmaceutical Co., Ltd, not yet recruiting.
A phase 2 trial of pembrolizumab, datopotamab deruxtecan and carboplatin in lung cancer, run by Latin American Cooperative Oncology Group, now recruiting.
A phase 2/3 trial of izalontamab brengitecan, paclitaxel / nab-paclitaxel and carboplatin in lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., not yet recruiting.
A phase 3 trial of QLC5508, QL2107, tislelizumab, carboplatin and other drugs in lung cancer, run by Qilu Pharmaceutical Co., Ltd., not yet recruiting.
A phase 2/3 trial of izalontamab brengitecan, tislelizumab, pemetrexed, carboplatin and other drugs in lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., not yet recruiting.
A phase 3 trial of adebrelimab, cisplatin, carboplatin, pemetrexed and other drugs in lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., not yet recruiting.
A phase 1/2 trial of ivonescimab, datopotamab deruxtecan and osimertinib in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.
A phase 2 trial of SYS6010, osimertinib, pemetrexed, cisplatin and other drugs in lung cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., not yet recruiting.
A phase 3 trial of SYS6010, tislelizumab, toripalimab, durvalumab and other drugs in lung cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., not yet recruiting.